• Home
• Research
• Specialized Working Groups
• Immune Therapies for Hematologic Disorders
• Publications

Publications

• The EBMT/EHA CAR-T Cell Handbook
  Editors: Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele.
  2022, ISBN 978-3-030-94352-3 ISBN 978-3-030-94353-0 (eBook).
  
  
• Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma
  Munawar U, Zhou X, Prommersberger S, Nerreter S, Vogt C, Steinhardt MJ, Truger M, Mersi J, Teufel E, Han S, Haertle L, Banholzer N, Eiring P, Danhof S, Navarro-Aguadero MA, Fernandez-Martin A, Ortiz-Ruiz A, Barrio S, Gallardo M, Valeri A, Castellano E, Raab P, Rudert M, Haferlach C, Sauer M, Hudecek M, Martinez-Lopez J, Waldschmidt J, Einsele H, Rasche L, Kortüm KM.
  Commun Biol. 2023 Dec 21;6(1):1299.
  
  
• Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
  Moreau P, Mateos MV, Gonzalez Garcia ME, Einsele H, De Stefano V, Karlin L, Lindsey-Hill J, Besemer B, Vincent L, Kirkpatrick S, Delforge M, Perrot A, van de Donk NWCJ, Pawlyn C, Manier S, Leleu X, Martinez-Lopez J, Ghilotti F, Diels J, Morano R, Albrecht C, Strulev V, Haddad I, Pei L, Kobos R, Smit J, Slavcev M, Marshall A, Weisel K
  Adv Ther. 2024 Feb;41(2):696-715.
  
  
• Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
  Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, Chojnacka M, Cirrincione A, Durante M, Tilmont R, Barakat E, Poorebrahim M, Sinha S, McIntyre J, M Y Chan A, Wilson H, Kyman S, Krishnan A, Landgren O, Walter W, Meggendorfer M, Haferlach C, Haferlach T, Einsele H, Kortüm MK, Knop S, Alberge JB, Rosenwald A, Keats JJ, Rasche L, Maura F, Neri P, Bahlis NJ.
  Nat Med. 2023 Sep;29(9):2295-2306.
  
  
• Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)
  Cesaro S, Mikulska M, Hirsch HH, Styczynski J, Meylan S, Cordonnier C, Navarro D, von Lilienfeld-Toal M, Mehra V, Marchesi F, Besson C, Masculano RC, Beutel G, Einsele H, Maertens J, de la Camara R; ECIL 9; Ljungman P, Pagano L.
  Leukemia. 2023 Sep;37(9):1933-1938.
  
  
• Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma
  Kegyes D, Gulei D, Drula R, Cenariu D, Tigu B, Dima D, Tanase A, Badelita S, Buzoianu AD, Ciurea S, Ghiaur G, Terpos E, Ciechanover A, Einsele H, Tomuleasa C.
  Blood Rev. 2023 Sep;61:101100.
  
  
• Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
  Ludwig H, Terpos E, van de Donk N, Mateos MV, Moreau P, Dimopoulos MA, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, Gay F, Einsele H, Mina R, Caers J, Driessen C, Musto P, Zweegman S, Engelhardt M, Cook G, Weisel K, Broijl A, Beksac M, Bila J, Schjesvold F, Cavo M, Hajek R, Touzeau C, Boccadoro M, Sonneveld P.
  Lancet Oncol. 2023 Jun;24(6):e255-e269.
  
  
• Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
  Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F, van de Donk NWCJ, Ntanasis-Stathopoulos I, Vangsted AJ, Driessen C, Schjesvold F, Cerchione C, Zweegman S, Hajek R, Moreau P, Einsele H, San-Miguel J, Boccadoro M, Dimopoulos MA, Sonneveld P, Ludwig H.
  Leukemia. 2023 Jun;37(6):1175-1185.
  
  
• Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing
  Huisman W, Roex MCJ, Hageman L, Koster EAS, Veld SAJ, Hoogstraten C, van Balen P, van Egmond HM, van Bergen CAM, Einsele H, Germeroth L, Amsen D, Falkenburg JHF, Jedema I.
  Blood Adv. 2023 Mar 14;7(5):812-827.
  
  
• Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
  Gagelmann N, Wulf GG, Duell J, Glass B, van Heteren P, von Tresckow B, Fischer M, Penack O, Ayuk F, Einsele H, Holtick U, Thomson J, Dreger P, Kröger N.
  Blood Adv. 2023 Feb 28;7(4):555-559.
  
  
• Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial
  Ngai LL, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland MAMA, Fayed MMHE, Kelder A, Oudshoorn-van Marsbergen L, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Griškevičius L, Juliusson G, van de Loosdrecht AA, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Löwenberg B, de Leeuw DC, Janssen JJWM, Ossenkoppele GJ, Cloos J.
  Blood. 2023 May 25;141(21):2657-2661.
  
  
• Dysregulation of developmental and cell type-specific expression of glycoconjugates on hematopoietic cells: a new characteristic of myelodysplastic neoplasms (MDS)
  van Spronsen MF, Horrevorts S, Cali C, Westers TM, Van Gassen S, Saeys Y, van Vliet SJ, van Kooyk Y, van de Loosdrecht AA.
  Leukemia. 2023 Mar;37(3):702-707.
  
  
• Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
  Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Adès L, Borate U, Bowen D, Buckstein R, Brunner A, Carraway HE, Daver N, Díez-Campelo M, de Witte T, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner M, Komrokji R, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz G, Scheinberg P, Stauder R, van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P.
  Blood. 2023 Apr 27;141(17):2047-2061.
  
  
• Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study
  Baron F, Nagler A, Galimard JE, Sanz J, Versluis J, Forcade E, Chevallier P, Sirvent A, Anthias C, Kuball J, Furst S, Rambaldi A, Sierra J, von dem Borne PA, Gallego Hernanz MP, Cluzeau T, Robinson S, Raiola AM, Labussière-Wallet H, Byrne JL, Malfuson JV, Ruggeri A, Mohty M, Ciceri F.
  Br J Haematol. 2024 Jan;204(1):250-259.
  
  
• Age, CD34+ cell dose, conditioning and pre-transplant cytopenias can help predict transfusion support in lymphoma patients undergoing autologous stem cell transplantation
  Regalado-Artamendi I, García-Fasanella M, Medina L, Fernandez-Sojo J, Esquirol A, García-Cadenas I, Martino R, Briones J, Sierra J, Novelli S.
  Vox Sang. 2023 Aug;118(8):681-689.
  
  
• Clothing as a potential exposure source of trace elements during early life
  Herrero M, Rovira J, González N, Marquès M, Barbosa F, Sierra J, Domingo JL, Nadal M, Souza MCO.
  Environ Res. 2023 Sep 15;233:116479.
  
  
• Correction to: High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion
  Caballero AC, Escribà-Garcia L, Pujol-Fernández P, Escudero-López E, Ujaldón-Miró C, Montserrat-Torres R, Sierra J, Alvarez-Fernández C, Briones J.
  Cancer Gene Ther. 2023 Jan;30(1):219.
  
  
• Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR
  Manfredi F, Stasi L, Buonanno S, Marzuttini F, Noviello M, Mastaglio S, Abbati D, Potenza A, Balestrieri C, Cianciotti BC, Tassi E, Feola S, Toffalori C, Punta M, Magnani Z, Camisa B, Tiziano E, Lupo-Stanghellini MT, Branca RM, Lehtiö J, Sikanen TM, Haapala MJ, Cerullo V, Casucci M, Vago L, Ciceri F, Bonini C, Ruggiero E.
  Sci Adv. 2023 Dec;9(48):eadg8014.
  
  
• Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
  Bonini C, Chapuis AG, Hudecek M, Guedan S, Magnani C, Qasim W. Genome Editing in Engineered T Cells for Cancer Immunotherapy. Hum Gene Ther. 2023 Sep;34(17-18):853-869. doi: 10.1089/hum.2023.128.
  Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C, Ciceri F, Corradini P, Delgado J, Di Blasi R, Greco R, Houot R, Iacoboni G, Jäger U, Kersten MJ, Mielke S, Nagler A, Onida F, Peric Z, Roddie C, Ruggeri A, Sánchez-Guijo F, Sánchez-Ortega I, Schneidawind D, Schubert ML, Snowden JA, Thieblemont C, Topp M, Zinzani PL, Gribben JG, Bonini C, Sureda A, Yakoub-Agha I.
  Blood. 2023 Sep 7;142(10):865-877.
  
  
• An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA
  Rejeski K, Greco R, Onida F, Sánchez-Ortega I, Bonini C, Sureda A, Gribben JG, Yakoub-Agha I, Subklewe M.
  Hemasphere. 2023 Apr 27;7(5):e889.
  
  
• Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities
  Spanjaart AM, Pennings ERA, Kos M, Mutsaers PGNJ, Lugtenburg PJ, van Meerten T, van Doesum JA, Minnema MC, Jak M, van Dorp S, Vermaat JSP, van der Poel MWM, van Oijen MGH, Kuipers MT, Nijhof IS, Kersten MJ.
  JCO Oncol Pract. 2023 Mar;19(3):e407-e416.
  
  
• ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0
  Kiesewetter B, Dafni U, de Vries EGE, Barriuso J, Curigliano G, González-Calle V, Galotti M, Gyawali B, Huntly BJP, Jäger U, Latino NJ, Malcovati L, Oosting SF, Ossenkoppele G, Piccart M, Raderer M, Scarfò L, Trapani D, Zielinski CC, Wester R, Zygoura P, Macintyre E, Cherny NI; ESMO-MCBS Working Group and Extended Working Group.
  Ann Oncol. 2023 Sep;34(9):734-771.
  
  
• CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses
  Bove C, Arcangeli S, Falcone L, Camisa B, El Khoury R, Greco B, De Lucia A, Bergamini A, Bondanza A, Ciceri F, Bonini C, Casucci M.
  J Immunother Cancer. 2023 Jan;11(1):e005878.
  
  
• Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations
  Ammar D, Schapitz I, Luu M, Hudecek M, Meyer M, Taps T, Schröder B, Ivics Z, Sanges C, Franz P, Koehl U, Negre H, Johanna I, Awigena-Cook J.
  Front Immunol. 2023 Nov 24;14:1280826.
  
  
• Learning from the microbes: exploiting the microbiome to enforce T cell immunotherapy
  Staudt S, Ziegler-Martin K, Visekruna A, Slingerland J, Shouval R, Hudecek M, van den Brink M, Luu M.
  Front Immunol. 2023 Sep 18;14:1269015.
  
  
• Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
  Althaus J, Nilius-Eliliwi V, Maghnouj A, Döring S, Schroers R, Hudecek M, Hahn SA, Mika T.
  Cancer Immunol Immunother. 2023 Aug;72(8):2573-2583.
  
  
• Teclistamab impairs detection of BCMA CAR-T cells
  Glatte B, Wenk K, Grahnert A, Friedrich M, Merz M, Vucinic V, Fischer L, Reiche K, Alb M, Hudecek M, Franz P, Fricke S, Platzbecker U, Koehl U, Sack U, Boldt A, Hauschildt S, Weiss R.
  Blood Adv. 2023 Aug 8;7(15):3842-3845.
  
  
• CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach
  Dreger P, Corradini P, Gribben JG, Glass B, Jerkeman M, Kersten MJ, Morschhauser F, Mussetti A, Viardot A, Zinzani PL, Sureda A; European Society for Blood and Marrow Transplantation and the European Hematology Association Lymphoma Group.
  Lancet Haematol. 2023 Dec;10(12):e1006-e1015.
  
  
• A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
  Dickinson MJ, Barba P, Jäger U, Shah NN, Blaise D, Briones J, Shune L, Boissel N, Bondanza A, Mariconti L, Marchal AL, Quinn DS, Yang J, Price A, Sohoni A, Treanor LM, Orlando EJ, Mataraza J, Davis J, Lu D, Zhu X, Engels B, Moutouh-de Parseval L, Brogdon JL, Moschetta M, Flinn IW.
  Cancer Discov. 2023 Sep 6;13(9):1982-1997.